Formula I Compounds for Resistant Mycobacterial Infections
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current tuberculosis therapies are lengthy, complex, and ineffective against emerging resistant strains of Mycobacterium tuberculosis, necessitating the development of new agents that can reduce treatment duration and efficacy against multi-drug resistant and extensively drug resistant TB.
Innovation Solution
Development of compounds of Formula I, which are used to treat mycobacterial infections, including resistant strains of Mycobacterium tuberculosis, by employing specific chemical structures that exhibit anti-mycobacterial activity, and can be combined with existing antibacterial agents for enhanced therapeutic effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current tuberculosis therapies are used, then treatment effectiveness against sensitive strains is maintained, but treatment duration is lengthy and complexity increases
Solution Approach 1:
The patent modifies the core chemical structure by varying parameters such as the substituent R1 (halogen, alkyl, aryl, heteroaryl groups), the linker length (n = 0, 1, or 2), and the terminal group R2 (aryl, heterocyclic, alkyl-substituted groups) to create a series of compounds with optimized anti-mycobacterial activity, aiming to reduce treatment duration while maintaining effectiveness
Solution Approach 2:
The compounds represent composite molecular structures combining a core chromen-2-one scaffold with various aromatic and heterocyclic substituents, creating hybrid molecules that integrate multiple functional groups to enhance potency and broaden spectrum against resistant strains
2Reliability
If current tuberculosis therapies are used, then treatment protocol is established, but complexity of therapy increases
Solution Approach 1:
The patent segments the complex treatment approach by developing individual compound series (Formula I with various R1 and R2 substitutions) that can be evaluated separately, allowing identification of lead compounds with simplified monotherapy or combination regimens to reduce overall therapeutic complexity
3Reliability
If new compounds are developed to target resistant strains, then efficacy against resistant mutants is improved, but development complexity increases
Solution Approach 1:
The patent applies local quality by introducing specific functional groups at particular positions on the core structure (e.g., electron-withdrawing groups at R1, specific heterocyclic groups at R2) to enhance interaction with target enzymes in resistant strains, creating localized chemical modifications that boost efficacy without requiring complete structural redesign
Data Source
AI summary
The invention relates to compounds of Formula I or a pharmaceutically acceptable salt, ester or prodrug thereof: